8-K: OrthoPediatrics Corp. Announces Record Full Year 2024 Financial Results, Revenue Up 38%

OrthoPediatrics Corp. reports a 38% increase in full year 2024 revenue, reaching $204.7 million, and more than doubles fourth quarter 2024 adjusted EBITDA.

Summary

• OrthoPediatrics Corp. announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company reported a 40% increase in revenue for the fourth quarter of 2024, reaching $52.7 million, compared to $37.6 million in the same period last year.
• Domestic revenue increased by 52% and international revenue increased by 5% in the fourth quarter.
• Adjusted EBITDA for the fourth quarter of 2024 was $3.0 million, compared to $1.3 million in the fourth quarter of 2023.
• Full year 2024 revenue reached a record $204.7 million, a 38% increase from $148.7 million in 2023.
• Domestic revenue increased by 45% and international revenue increased by 15% for the full year.
• The company achieved a record full year adjusted EBITDA of $8.5 million in 2024, compared to $5.0 million in 2023.
• OrthoPediatrics reduced fourth quarter 2024 free cash flow usage by 70% compared to the third quarter 2024 year to date average.
• The company anticipates its first full quarter of positive free cash flow in the fourth quarter of 2025.
• OrthoPediatrics reiterated its full year 2025 revenue guidance to be in the range of $235.0 million to $242.0 million, representing growth of 15% to 18% compared to 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and improved profitability, although some concerns exist regarding increased operating expenses and net losses.

Positives

• The company helped a record number of children, exceeding 1.14 million since its inception.
• Revenue increased significantly in both the fourth quarter and full year 2024.
• Adjusted EBITDA improved in both the fourth quarter and full year 2024.
• Free cash flow usage was reduced in the fourth quarter of 2024.
• The company expects positive free cash flow in the fourth quarter of 2025.
• Revenue guidance for 2025 indicates continued growth.

Negatives

• Gross profit margin decreased in the fourth quarter and full year 2024, primarily due to the reclassification of certain labor and overhead expenses related to the Boston O&P manufacturing business.
• Total operating expenses increased in the fourth quarter and full year 2024.
• The company reported a net loss for the fourth quarter and full year 2024.
• Total other expense was $2.4 million for the fourth quarter of 2024, compared to other income of $1.2 million for the same period last year.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• The company's performance is subject to the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus.
• The company's future performance is subject to the risks, uncertainties, and factors set forth in OrthoPediatrics' Annual Report on Form 10-K filed with the SEC on March 8, 2024.

Future Outlook

The company expects its revenue to be in the range of $235.0 million to $242.0 million for full year 2025, representing growth of 15% to 18% over 2024 revenue, and expects to generate $15.0 million to $17.0 million of adjusted EBITDA for full year 2025.

Management Comments

• 2024 was yet another year that OrthoPediatrics delivered strong results, successfully executed on our strategy, and further solidified our market leading position as we surround the pediatric orthopedic surgeon with all of the technology they need, commented David Bailey, President & CEO of OrthoPediatrics.
• Looking ahead, we are positioned well to further build on our past success and achieve our long-term goal of helping one million kids per year.
• We will help more children than ever, capture more share across the entire business as we continue to break revenue records, grow our adjusted EBITDA, and improve cash usage in 2025 and beyond, and we look forward to driving our Company through this next phase of growth.

Industry Context

OrthoPediatrics is focused exclusively on advancing the field of pediatric orthopedics, which positions it uniquely in the orthopedic market.

Comparison to Industry Standards

• It is difficult to compare OrthoPediatrics directly to larger orthopedic companies like Johnson & Johnson, Stryker, or Zimmer Biomet, as they have broader product portfolios and serve both adult and pediatric markets.
• However, OrthoPediatrics' growth rate of 38% in revenue significantly outpaces the overall orthopedic market growth, which is typically in the mid-single digits.
• Within the pediatric segment, there are few direct competitors with a similar comprehensive product offering, making OrthoPediatrics a market leader in this niche.

Stakeholder Impact

• Shareholders can expect continued growth and improved profitability.
• Employees may benefit from the company's expansion and success.
• Customers (pediatric orthopedic surgeons) will have access to a comprehensive product offering.
• The company's success will improve the lives of children with orthopedic conditions.

Next Steps

• The company will host a conference call on March 4, 2025, to discuss the results.
• The company will continue to execute its strategy to further solidify its market leading position.
• The company will focus on helping more children, capturing more market share, growing adjusted EBITDA, and improving cash usage in 2025 and beyond.

Key Dates

Keywords

OrthoPediatrics, financial results, pediatric orthopedics, revenue, adjusted EBITDA, growth, earnings, KIDS